NASDAQ · NBIX
Neurocrine Biosciences, Inc.
$146.38+$0.85 (+0.58%)
Neurocrine Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.35% below the high.
Loading market information…
NASDAQ · PRAX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Praxis Precision Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Praxis Precision Medicines, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$3.54. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Praxis Precision Medicines, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 2, 2025 | -$3.29-2.81% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q4 2024 | Feb 28, 2025 | -$2.94-6.52% vs estimate | $7.46M+2,405.37% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | -$2.75-36.82% vs estimate | $302.00K-17.26% vs estimate |
|---|
THE ANALYST VIEW
18 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 13 contributors · Median target $575.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$146.38+$0.85 (+0.58%)
Neurocrine Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.35% below the high.
$143.45-$0.06 (-0.04%)
Axsome Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.87% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
$20.76+$0.44 (+2.17%)
Acadia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.95% below the high.
$19.32+$0.03 (+0.16%)
Denali Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
$41.84+$0.76 (+1.85%)
Supernus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.89% below the high.
$24.21+$1.71 (+7.6%)
Rapport Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 54.26% below the high.
$1.30$0.00 (0.0%)
Anavex Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.43% below the high.
